performed tumor gene analysis in 17 patients who had acquired tolerance to PD-L1 antibodies and identified secreted RNA splicing of PD-L1 protein variants in four patients, which competitively neutralized anti-PD-L1 antibody activity [60]. This evidence concerns the gene CD274 and neoplasm.